Combination antifungal therapy for Scedosporium species in cystic fibrosis.
Lomentospora prolificans
Scedosporium apiospermum
antifungal
cystic fibrosis
posaconazole
terbinafine
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
07
02
2020
revised:
08
04
2020
accepted:
11
04
2020
pubmed:
28
4
2020
medline:
1
12
2020
entrez:
28
4
2020
Statut:
ppublish
Résumé
To evaluate safety and efficacy of oral posaconazole and terbinafine for Lomentospora prolificans and Scedosporium apiospermum in children with cystic fibrosis. Retrospective case review. There were five children (four girls), median age 15.0 years; three had S. apiospermum and two had L. prolificans. Treatment duration: median 5 months (range: 5-18 m). In no patient was eradication achieved, with the follow-up range being 6 months to 4 years. Effect on lung function was variable but encouraging. No adverse effects were reported, one child had transient elevation of liver enzymes. While the combination therapy was well tolerated, it was unsuccessful at eradication.
Substances chimiques
Antifungal Agents
0
Triazoles
0
posaconazole
6TK1G07BHZ
Terbinafine
G7RIW8S0XP
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1993-1995Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Sedlacek L, Graf B, Schwarz C, et al. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium. J Cyst Fibros. 2015;14:237-241.
Engel TGP, Slabbers L, de Jong C, et al. Dutch Cystic fibrosis Fungal Collection Consortium. Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients-A Dutch, multicentre study. J Cyst Fibros. 2019;18:221-226.
Hong G, Lechtzin N, Hadjiliadis D, Kawut SM. Inhaled antibiotic use is associated with Scedosporium/Lomentospora species isolation in cystic fibrosis. Pediatr Pulmonol. 2019;54:133-140.
Schwarz C, Brandt C, Melichar V, et al. Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis. J Cyst Fibros. 2019;18:227-232.
Solé A, García-Robles AA, Jordá C, et al. Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection. Am J Transplant. 2018;18:504-509.
Tortorano AM, Richardson M, Roilides E, et al. European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20(Suppl 3):27-46.
Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, et al. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother. 2008;52:1136-1139.